Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONKORAS-101: BBO-8520 in Advanced KRASG12C Mutant NSCLC
NCT06343402Phase 1Recruiting
- Sponsor
- TheRas, Inc.
- Start
- May 2024
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BBO-8520 in non-small cell lung cancer (NSCLC) (8 cohorts), sponsored by TheRas, Inc. Primary endpoints: Adverse Events at 3 years and Dose-limiting toxicities at 3 years. Started May 2024; status: recruiting.
02
Drugs
BBO-8520
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06343402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343402.